On August 28, Xinjiang Bai Hua Cun Pharma Tech Co.,Ltd. hit the daily limit down during intraday trading. Wind data shows that by the close of trading on August 28, the company's shares settled at 15.44 yuan per share, reflecting a closing decline of 7.43%. However, the stock's cumulative gain since the start of August still stands at a substantial 119.63%.
Responding to the sharp drop, Xinjiang Bai Hua Cun Pharma Tech Co.,Ltd. exclusively told reporters that share prices are influenced by multiple factors. The company primarily focuses on generic drug CRO services, with its innovative drug CRO business representing only a very small portion. Compared with generic drugs, innovative drugs involve larger investments and carry a higher risk of returns falling short of expectations. The company operates as an upstream supplier to pharmaceutical manufacturers, with its CRO business directly engaging drug makers. Depending on the complexity of the generic drug replication, the total order value varies, and orders typically span no less than one year, usually ranging from two to three years. Competition in the generic drug CRO industry is intensifying, creating a buyer's market where the company must actively seek out business, and unit order prices are not as high as in previous years.
According to Xinjiang Bai Hua Cun Pharma Tech Co.,Ltd.'s 2026 semi-annual report, the company operates in the pharmaceutical research and development services industry, primarily focusing on small molecule chemical drug R&D, registration applications, and pharmaceutical intermediate development. It organizes Phase I-IV clinical trials, bioequivalence studies, medical science services, R&D project consulting, data management and statistical services, and third-party testing (including bio-sample analysis, packaging material compatibility, and genotoxic impurity analysis), offering one-stop, full-process pharmaceutical R&D services as a comprehensive CRO company delivering integrated solutions. During the reporting period, the company achieved total operating revenue of approximately 157 million yuan, a year-on-year decrease of 22.13%; net profit attributable to shareholders of the listed company was 14.7603 million yuan, down 42.08% year-on-year; and non-GAAP net profit was 12.1863 million yuan, a year-on-year decline of 49.35%.
Notably, the post-market trading data on August 28 showed that the top five buying and selling trading departments for the stock generated a total transaction volume of 373 million yuan, with purchase turnover at 178 million yuan and sales turnover at 194 million yuan, resulting in a combined net sell of 16.341 million yuan. Specifically, among the listed trading departments, the largest buyer was Guosen Securities Co., Ltd. Zhejiang Internet Branch, with a purchase amount of 52.6024 million yuan, while the largest seller was China CICC Wealth Securities Co., Ltd. Hunan Branch, with a sales amount of 60.7041 million yuan. Over the past six months, the stock has appeared on the trading data list 20 times.
Additionally, on the same evening, Xinjiang Bai Hua Cun Pharma Tech Co.,Ltd. released an announcement regarding a shareholder's planned share reduction. The announcement stated that Li Jiancheng, a shareholder holding less than 5% of the company's shares, intends to reduce his holdings by 1 million shares through centralized bidding trading within three months starting 15 trading days after the announcement date, citing personal capital needs.